Table 1 Characteristics of Study Patients
From: Detection of adverse drug events in e-prescribing and administrative health data: a validation study
|  | All Study Patients (N = 688) | Patients Prescribed an Antidepressant (N = 302) | Patients Prescribed an Antihypertensive (N = 386) |
|---|---|---|---|
Age, mean (SD) | 64.2 (13.9) | 59.5 (16.2) | 67.8 (10.6) |
Sex (male) | 243 (35.3%) | 94 (31.1%) | 149 (38.6%) |
Most Commonly Prescribed Drug Classes | |||
 Antidepressants | |||
  SSRIs | 117 (17.0%) | 117 (38.7%) | NA |
  SNRIs | 104 (15.1%) | 104 (34.4%) | NA |
  SRIs | 50 (7.3%) | 50 (16.6%) | NA |
 Antihypertensives | |||
  Calcium Channel Blockers | 116 (16.9%) | NA | 116 (30.1%) |
  Angiotensin II Receptor Blockers | 113 (16.4%) | NA | 113 (29.3%) |
  Thiazide Diuretics | 50 (7.3%) | NA | 50 (13.0%) |
Most Commonly Prescribed Medications | |||
 Antidepressants | |||
  Citalopram | 90 (13.1%) | 90 (29.8%) | NA |
  Trazodonea | 50 (7.3%) | 50 (16.6%) | NA |
  Venlafaxine | 44 (6.4%) | 44 (14.6%) | NA |
 Antihypertensives | |||
  Amlodipine | 69 (10.0%) | NA | 69 (17.9%) |
  Hydrochlorothiazide | 45 (6.5%) | NA | 45 (11.7%) |
  Telmisartan | 32 (4.7%) | NA | 32 (8.3%) |
Most Common Therapeutic Indications | |||
 Antidepressants | |||
  Depression | 121 (17.6%) | 121 (40.1%) | NA |
  Generalized Anxiety Discorder | 62 (9.0%) | 62 (20.5%) | NA |
  Insomnia | 52 (7.6%) | 52 (17.2%) | NA |
 Antihypertensives | |||
  Hypertension | 306 (44.5%) | NA | 306 (79.3%) |
  Oedema | 18 (2.6%) | NA | 18 (4.7%) |
Number of Concurrent Medicationsb | 3.7 (2.9) | 3.8 (2.9) | 3.7 (2.9) |
Charlson Comorbidity Index Score | |||
  0 | 334 (48.5%) | 165 (54.6%) | 169 (43.8%) |
  1 | 166 (24.1%) | 73 (24.2%) | 93 (24.1%) |
  2+ | 188 (27.3%) | 64 (21.2%) | 124 (32.1%) |
Most Common Comorbidities | |||
  Chronic Pulmonary Disease | 149 (21.7%) | 68 (22.5%) | 81 (21.0%) |
  Diabetes (without complications) | 105 (15.3%) | 36 (11.9%) | 69 (17.9%) |
  Renal Disease | 66 (9.6%) | 21 (7.0%) | 45 (11.7%) |
  Congestive Heart Failure | 58 (8.4%) | 18 (6.0%) | 40 (10.4%) |
  Cerebrovascular Disease | 48 (7.0%) | 20 (6.6%) | 28 (7.3%) |